{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:51:08Z","timestamp":1791816668268,"version":"4.3.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371268"],"award-info":[{"award-number":["82371268"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan Project","award":["2020ZX17"],"award-info":[{"award-number":["2020ZX17"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231125"],"award-info":[{"award-number":["BK20231125"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Project of Jiangsu Provincial Health Commission","award":["K2023031"],"award-info":[{"award-number":["K2023031"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of direct switch from levodopa\/benserazide (LB) to levodopa\/carbidopa\/entacapone (LCE) versus LB plus pramipexole (PPX) in Chinese patients with Parkinson\u2019s disease (PD) experiencing wearing off (WO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, prospective, randomized, open-label, observational study, 140 patients with PD experiencing WO who had been on stable LB treatment were enrolled and randomized 3:2 to receive LCE (84) or LB\u202f+\u202fPPX (56) treatment for 8\u202fweeks. The primary endpoint was change in the daily \u201cOFF\u201d time from baseline. Change in the daily \u201cON\u201d time was also assessed. Treatment-emergent adverse events (TEAEs) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-nine patients in the LCE group and 49 patients in the PPX group completed the study. Both LCE and PPX shortened the patients\u2019 daily OFF time significantly after 8\u202fweeks (\u22121.76\u202f\u00b1\u202f1.70\u202fh,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001 and \u22121.51\u202f\u00b1\u202f1.60,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001, respectively), and the shortenings were comparable between the two groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.414). Correspondingly, both the LCE group and the PPX group had significantly increased daily ON time (1.62\u202f\u00b1\u202f1.59\u202fh,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001 and 1.38\u202f\u00b1\u202f1.65,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001, respectively), and the increases were comparable between the two groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.412). Both treatments improved the patients\u2019 WO symptoms, sleep quality, depression and quality of life. Six (7.59%) patients in the LCE group and 7 (14.29%) patients in the PPX group reported TEAEs, all of which were mild and tolerable. One patient in the LCE group and 2 patients in the PPX group experienced mild dyskinesia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LCE and LB\u202f+\u202fPPX were both effective, safe and tolerable in treating patients with PD who experienced WO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1682614","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:26Z","timestamp":1763529506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Levodopa\/carbidopa\/entacapone versus levodopa\/benserazide plus pramipexole in Chinese patients with Parkinson\u2019s disease experiencing wearing off"],"prefix":"10.3389","volume":"16","author":[{"given":"Cuiyu","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/ern.11.203","article-title":"Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa\/carbidopa\/entacapone","volume":"12","author":"Reichmann","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2147\/TCRM.S163190","article-title":"Levodopa\/carbidopa\/entacapone versus levodopa\/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation","volume":"14","author":"Yi","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40265-019-01098-w","article-title":"Contemporary options for the Management of Motor Complications in Parkinson's disease: updated clinical review","volume":"79","author":"Cabreira","year":"2019","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/ndt.s1660","article-title":"Optimizing levodopa therapy for Parkinson's disease with levodopa\/carbidopa\/entacapone: implications from a clinical and patient perspective","volume":"4","author":"Brooks","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(05)70801-1","article-title":"Parkinson's disease in China: prevalence in Beijing, xian, and Shanghai","volume":"365","author":"Zhang","year":"2005","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40035-019-0162-z","article-title":"Parkinson's disease in China: a forty-year growing track of bedside work","volume":"8","author":"Li","year":"2019","journal-title":"Transl Neurodegener"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3109\/00207454.2011.598982","article-title":"Immediate versus delayed switch from levodopa\/carbidopa to levodopa\/carbidopa\/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off","volume":"121","author":"Lew","year":"2011","journal-title":"Int J Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/ndt.s5190","article-title":"Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa\/levodopa\/entacapone (Stalevo)","volume":"6","author":"Solla","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref9","first-page":"1","article-title":"Carbidopa\/levodopa\/entacapone: the evidence for its place in the treatment of Parkinson's disease","volume":"5","author":"Poulopoulos","year":"2010","journal-title":"Core Evid"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ene.15994","article-title":"Stalevo\u00ae: a pioneering treatment for OFF periods in Parkinsons disease","volume":"30","author":"Jenner","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1212\/wnl.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00702-004-0190-3","article-title":"Clinical advantages of COMT inhibition with entacapone - a review","volume":"111","author":"Gordin","year":"2004","journal-title":"J Neural Transm (Vienna)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00702-009-0344-4","article-title":"Direct switch from levodopa\/benserazide or levodopa\/carbidopa to levodopa\/carbidopa\/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study","volume":"117","author":"Eggert","year":"2010","journal-title":"J Neural Transm (Vienna)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000086479","article-title":"Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa\/carbidopa\/entacapone) and levodopa\/DDCI given in combination with Comtess\/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa\/DDCI treatment","volume":"53","author":"Brooks","year":"2005","journal-title":"Eur Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11055-007-0050-3","article-title":"Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease","volume":"37","author":"Fedorova","year":"2007","journal-title":"Neurosci Behav Physiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/DDDT.S112723","article-title":"Analysis of pramipexole dose-response relationships in Parkinson's disease","volume":"11","author":"Wang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00702-006-0554-y","article-title":"Development of a patient questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease","volume":"114","author":"Stacy","year":"2007","journal-title":"J Neural Transm (Vienna)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00702-004-0184-1","article-title":"An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off","volume":"112","author":"Koller","year":"2005","journal-title":"J Neural Transm (Vienna)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"8834950","DOI":"10.1155\/2021\/8834950","article-title":"Efficacy and safety of pramipexole sustained release versus immediate release formulation for nocturnal symptoms in Chinese patients with advanced Parkinson's disease: a pilot study","volume":"2021","author":"Zhou","year":"2021","journal-title":"Parkinsons Dis"},{"key":"ref23","first-page":"245","article-title":"Levodopa\/carbidopa intestinalis g\u00e9l kezel\u00e9s hat\u00e1sa az \u00e9letmin\u0151s\u00e9gre [the impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease]","volume":"67","author":"Kov\u00e1cs","year":"2014","journal-title":"Ideggyogy Sz"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Determination of minimal clinically important change in early and advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.4103\/neuroindia.NI_597_16","article-title":"Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa\/carbidopa\/entacapone","volume":"65","author":"Park","year":"2017","journal-title":"Neurol India"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/mds.23829","article-title":"The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"ref29","first-page":"973","article-title":"Chinese guidelines for the treatment of Parkinson\u2019s disease (4th Edition)","volume":"53","year":"2020","journal-title":"Chin J Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"Eur J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/wnl.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12883-022-02830-y","article-title":"Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"22","author":"Li","year":"2022","journal-title":"BMC Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.14802\/jmd.20055","article-title":"Therapeutic effect of levodopa\/carbidopa\/entacapone on sleep disturbance in patients with Parkinson's disease","volume":"13","author":"Park","year":"2020","journal-title":"J Mov Disord"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/mds.10508","article-title":"Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease","volume":"18","author":"Mizuno","year":"2003","journal-title":"Mov Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jns.2016.10.043","article-title":"Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease","volume":"372","author":"Zhu","year":"2017","journal-title":"J Neurol Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00702-008-0025-8","article-title":"Five-year efficacy and safety of levodopa\/DDCI and entacapone in patients with Parkinson's disease","volume":"115","author":"Brooks","year":"2008","journal-title":"J Neural Transm (Vienna)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-1331.2003.00559.x","article-title":"The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease","volume":"10","author":"Larsen","year":"2003","journal-title":"Eur J Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","article-title":"Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study","volume":"68","author":"Stocchi","year":"2010","journal-title":"Ann Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1353-8020(00)00031-6","article-title":"The long-term safety and efficacy of pramipexole in advanced Parkinson's disease","volume":"7","author":"Weiner","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","article-title":"Long-term use of pramipexole in the management of restless legs syndrome","volume":"13","author":"Lipford","year":"162012","journal-title":"Sleep Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40360-025-00886-3","article-title":"Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data","volume":"26","author":"Mu","year":"2025","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1682614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:34Z","timestamp":1763529514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1682614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":45,"alternative-id":["10.3389\/fneur.2025.1682614"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1682614","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1682614"}}